Other Names
Brain swelling, Cerebral oedema (British spelling), Intracranial swelling
Disease Roles
Neurotrauma/Traumatic brain injuryIschemic strokeBrain tumor

Cerebral edema Overview

Cerebral edema refers to the abnormal accumulation of fluid within either intracellular or extracellular compartments of the brain tissue. This leads to increased intracranial pressure which can impair nerve function and cause symptoms ranging from headache and nausea to seizures and coma; severe cases may result in death if untreated. The underlying mechanisms include disruption of blood-brain barrier integrity ("vasogenic"), cellular energy failure leading to ionic imbalance ("cytotoxic"), osmotic shifts ("osmotic"), or cerebrospinal fluid leakage into interstitial spaces ("interstitial"). Causes include trauma, ischemia/stroke, tumors, infections/inflammation, metabolic disturbances such as hyponatremia/hepatic failure, high altitude exposure among others. Management depends on etiology but often involves supportive care with airway protection and ICP monitoring plus medical/surgical interventions aimed at reducing brain volume/swelling through osmotherapy (mannitol/hypertonic saline), steroids where appropriate (tumor/inflammatory causes), surgical decompression when necessary—and experimental therapies targeting molecular mediators like ion channels involved in BBB dysfunction are under investigation.

Mechanism of Action

For drugs used: Osmotherapy increases plasma osmolality to draw water out of brain parenchyma into circulation. Steroids reduce blood-brain barrier permeability and inflammation. Diuretics promote systemic fluid loss. Experimental: Inhibition of specific ion channels/receptors implicated in BBB breakdown or astrocyte swelling (e.g., SUR1–TRPM4).

Biological Functions

Pathological accumulation of fluid within brain tissue leading to increased intracranial pressure and impaired neural function

Disease Associations

Neurotrauma/Traumatic brain injury
Ischemic stroke
Brain tumor
Central nervous system infection (e.g., meningitis, encephalitis)
High-altitude illness
Hepatic failure-associated encephalopathy

Safety Considerations

  • Risk of herniation due to rapid shifts in intracranial pressure during treatment
  • Rebound intracranial hypertension after osmotherapy withdrawal
  • Electrolyte imbalances from aggressive diuresis/osmotherapy
  • Limited efficacy window—irreversible damage can occur rapidly if untreated

Interacting Drugs

Mannitol
Hypertonic saline
Glucocorticoids
Dexamethasone
Furosemide
Barbiturates
Sedatives
Sulfonylureas

Associated Biomarkers

Biomarker
No established direct biomarkers for patient selection; diagnosis relies on imaging and clinical assessment. Some research focuses on markers like S100B protein or aquaporin expression levels, but these are investigational.